Chris Chamberlain

Translational research PhD student at the National Center for Cancer Immune Therapy (CCIT-DK) in Herlev, Denmark.

[Marco Donia @DoniaMarco]

A 8+ years journey bringing the first results. This is great news for patients and for science. Great work of the previous and current members of the TIL teams at @CCITdk and @NKI_nl

[Molecular Therapy Family of Journals @MolTherapy]

Researchers at @HerlevGentofte reported on highly efficient PD-1-targeted #CRISPR-Cas9 for tumor-infiltrating lymphocyte-based adoptive T #celltherapy in @moltherapy Oncolytics (#MTO). https://t.co/CVVzUKEhPw

[CCIT-DK: National Center for Cancer Immune Therapy @CCITdk]

Big day for @CCITdk! Basic discoveries from @CCITdk developed into a clinical trial at @CCITdk. Anti-PD1 #immunotherapy plus #vaccine against IDO/PD-L1, impressive response rates. Hope for more effective treatments for patients with #Melanoma #melsm #dkforsk

[CCIT-DK: National Center for Cancer Immune Therapy @CCITdk]

Improving #Immunotherapy monitoring, a new study from @AriannaDraghi @CAChamberlain_ and colleagues describing efficient identification of tumor-specific reactive tumor-infiltrating lymphocytes. Support by @cancer_dk @lundbeckfonden @DFF_raad @SSTSundhed @HerlevGentofte #dkforsk